The brand name is Journavx (NA refers to the sodium channel blocker aspect, and NAV is the gene that is targeted; X probably means they know it works on the NAV1.7 gene for people who experience genetically caused pain all the time, and are hoping it will work on other NAV1 genes for people with acquired neuropathic pain, such as pinched spinal nerves and diabetes).

IF it works on, say lumbrosacral radiculopathy, and IF Medicare will cover off-label RXs for office visit patients, we would probably have to give up Medicare Part C for Medicare to cover it. So that's something to think about if you take other expensive drugs, or see doctors less expensively with Part C than without.

It sounds like Vertex is going to do a larger Phase III trial. I wonder if they are enrolling patients for the trial yet.